Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-26

Study Completion Date

2018-06-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study was an assessor-blind, balanced, parallel, randomized, two-treatment, comparative immunogenicity study of multiple doses of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6 mL; Intas Pharmaceuticals Ltd. proposed biosimilar INTP5 compared to innovator product, US-Neulasta) in healthy, adult, human subjects under fed conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

NCT04651036

Healthy

UNKNOWN PHASE1

Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers

NCT00938678

Healthy

COMPLETED PHASE1

A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

NCT03273842

Healthy Volunteers

COMPLETED PHASE1

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

NCT06711523

Neutropenia, Chemotherapy-Induced Febrile Breast Neoplasm Female

ACTIVE_NOT_RECRUITING PHASE3

Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

NCT02454530

Chemotherapy-Induced Neutropenia

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunogenicity Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors

The study staff taking care of subject's safety and the laboratory personnel doing the sample analysis of PK, PD, and immunogenicity data were blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

INTP5 biosimilar product

INTP5 subcutaneously at a dose of 6 mg/0.6 mL.

Group Type EXPERIMENTAL

INTP5

Intervention Type COMBINATION_PRODUCT

INTP5, a pegfilgrastim biosimilar to US Neulasta.

US Neulasta reference product

US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.

Group Type ACTIVE_COMPARATOR

US Neulasta

Intervention Type COMBINATION_PRODUCT

US Neulasta: FDA approved pegfilgrastim innovator product.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

INTP5

INTP5, a pegfilgrastim biosimilar to US Neulasta.

Intervention Type COMBINATION_PRODUCT

US Neulasta

US Neulasta: FDA approved pegfilgrastim innovator product.

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive) living in and around Ahmedabad city or western part of India.
2. Having body weight ≥50 kg and body mass index (BMI) between 18.5 and 29.9 (both inclusive), calculated as weight in kg/height in meter\^2.
3. Not having any significant disease in medical history or clinically significant abnormal findings during screening, abdominal ultrasonography, medical history, clinical examination, laboratory evaluations, 12-lead echocardiogram (ECG) and chest X-ray (posterior-anterior view; within the last 6 months) recordings.
4. Able to understand and comply with the study procedures, in the opinion of the investigator.
5. Able to give voluntary written informed consent for participation in the trial.
6. In case of female subjects:

* Surgically sterilized at least 6 months prior to study participation; Or If a woman of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.
* Serum pregnancy test (for female subjects) must be negative.

Exclusion Criteria

1. Known hypersensitivity to the study drug or its constituents and/or hypersensitivity to E. coli derived proteins, and/or previous exposure to the study drug.
2. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
3. Known case of hereditary fructose intolerance.
4. Subjects with latex allergies will be excluded as the needle cover on the single-use prefilled syringe contains dry natural rubber (latex).
5. Any clinically significant laboratory finding including absolute neutrophil count (ANC), platelet, red blood cells (RBC) count, and hemoglobin level at the time of screening.
6. Prior exposure to any peptide colony stimulating or growth factor, including erythropoietin, filgrastim or Pegfilgrastim; Prior exposure to any vaccines, immunoglobulin preparations or immunomodulators within the past 6 months prior to receiving first dose; evidence of E. coli diarrhea or diseases within 3 months.
7. Any history or presence of asthma (including aspirin-induced asthma) or nasal polyp or NSAIDs induced urticaria.
8. Subjects with a history of pulmonary infiltrate or pneumonia in the last 6 months.
9. History of any hematologic disease including sickle cell disorders.
10. Ingestion or use of any prescribed medication at any time within 1 month prior to receiving first dose.
11. Receipt of over-the-counter medicines which have not yet cleared from the body (5 half-lives must have passed for the medicine to be considered to have cleared from the body).
12. A recent history of harmful use of alcohol, i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40% distilled spirits, such as rum, whisky, brandy etc.) or consumption of alcohol or alcoholic products within 72 hours prior to receiving study medicine.
13. Smokers, who smoke 10 or more than 10 cigarettes/day or inability to abstain from smoking during the study.
14. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
15. Donation of blood (1 unit or 350 mL) or equivalent amount of blood substitute.
16. Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study.
17. Positive result for human immunodeficiency virus (HIV I \&/or II) and/or hepatitis B and C tests.
18. History or presence of cancer because of which anticipated life span is less than 5 years as per the investigator's assessment.
19. History or presence of psychiatric disorders.
20. Presence of tattoo or scars or any type of skin lesions due to infection, burning, wound or inflammation at the proposed site of injection.
21. An unusual diet, for whatever reason (e.g. low-sodium), for 4 weeks prior to receiving the study medicine. In any such case, subject selection will be at the discretion of the Principal Investigator.
22. Consumption of grape fruit or grape fruit products within 72 hours prior to receiving study drug.
23. A history of difficulty in donating blood.
24. Females, pregnant or lactating, or planning to become pregnant during the time the subject is on study or found positive in pregnancy test at screening.
25. Any infections in the last 4 weeks before receiving study medication.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes